Aeterna Zentaris, Inc. (USA) (NASDAQ:AEZS)
| CAPS Rating |
|
|---|---|
| Open | $1.70 |
| Previous Close | $1.70 |
| Daily Range | $1.63 - $1.70 |
| 52-Week Range | $1.35 - $2.68 |
| Market Cap | $159.55M |
| P/E Ratio | 0.00 |
| Dividend (Yield) | N/A (N/A) |
| Volume | 649,138 |
| Average Daily Volume | 0 |
AEZS
VS S&P 500 (SPY)
How do you think AEZS will perform against the market?
Caps
Motley Fool CAPS is a community working together to find better stocks and to become better investors.
AEZS Advanced Details
- CAPS Community Analysis: Commentary, Scorecard
- Advanced Financial Analysis: Historical Prices, Chart, Stats, Ratios, Earnings/Growth Rates, Statements, SEC Filings
AEZS News and Commentary
- Buy, Sell, or Hold: Ariad Pharmaceuticals – The Motley Fool
- Zacks #1 Rank Additions for Wednesday - Tale of the Tape – NASDAQ
- Zacks #1 Rank Additions for Thursday - Tale of the Tape – NASDAQ
- 2 High-Flying Biotechs Face a New Hurdle – The Motley Fool
- 3 Stocks Under $3 That Could Double in 2012 – The Motley Fool
- KERX Perifosine Analysis – Blog at The Motley Fool
- Don't Read Too Much Into This Partnership – The Motley Fool
- 2012 Preview: Aeterna Zentaris – The Motley Fool
- 3 Stock-Moving Binary Events to Watch in 2012 – The Motley Fool
- What to Look For From Keryx and Aeterna Zentaris in 2012 – The Motley Fool
- Geron's Hurry-Up-and-Wait Strategy – The Motley Fool
- 3 Biotech Stocks That Had a Bad 2011 – The Motley Fool
- Make Money in Strong Pharmaceutical Stocks the Easy Way – The Motley Fool
- Biotech Royalties, Almost as Good as Cash – The Motley Fool
- 2013 Is Closer Than You Think – The Motley Fool
- Breaking Down a Biotech Press Release – The Motley Fool
- I Was Wrong About Dendreon – The Motley Fool
- Make Money in Global Health-Care Stocks the Easy Way – The Motley Fool
- The Stocks Wall Street Loves – The Motley Fool
- Biotech Uncertainty = Big Upside Potential – The Motley Fool
RSS Headlines
Fool UK
